Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Tacrolimus may leads to higher clinical remission compared with placebo (low certainty).
Tacrolimus may leads to higher clinical improvement compared with placebo (low certainty).
It is very uncertain whether tacrolimus changes serious adverse events compared with placebo (very low certainty).
Tacrolimus showed no clear difference in total adverse events compared with placebo (low certainty).
It is very uncertain whether antioxidants changes live birth rate per couple randomised compared with placebo or no treatment (very low certainty).
Antioxidants may leads to higher clinical pregnancy rate per couple randomised compared with placebo or no treatment (low certainty).
It is very uncertain whether antioxidants changes adverse events ‐ Miscarriage compared with placebo or no treatment (very low certainty).
Antioxidants may leads to higher adverse events ‐ Gastrointestinal compared with placebo or no treatment (low certainty).
It is very uncertain whether summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy changes any severe adverse event (grade 3 or higher) (G3+ SevAE ) compared with placebo (maintenance therapy) (very low certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in overall survival (OS) compared with placebo after chemotherapy (maintenance therapy) (moderate certainty).
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… leads to lower progression‐free survival (PFS) compared with placebo after chemotherapy (maintenance therapy) (high certainty).
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… may leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with placebo after chemotherapy (maintenance therapy) (low certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy showed no clear difference in overall survival (OS) compared with placebo (maintenance therapy) (moderate certainty).
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy may leads to lower progression‐free survival (PFS) compared with placebo (maintenance therapy) (low certainty).
Intratympanic corticosteroids showed no clear difference in change in hearing threshold determined by PTA Range 0 dB to 140 dB… compared with no treatment or versus placebo (low certainty).
Intratympanic corticosteroids may leads to higher proportion of patients whose hearing is improved compared with no treatment or versus placebo (low certainty).